HRP20211081T1 - Anti-pro/latentna miostatinska protutijela i njihove uporabe - Google Patents
Anti-pro/latentna miostatinska protutijela i njihove uporabe Download PDFInfo
- Publication number
- HRP20211081T1 HRP20211081T1 HRP20211081TT HRP20211081T HRP20211081T1 HR P20211081 T1 HRP20211081 T1 HR P20211081T1 HR P20211081T T HRP20211081T T HR P20211081TT HR P20211081 T HRP20211081 T HR P20211081T HR P20211081 T1 HRP20211081 T1 HR P20211081T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- isolated
- seq
- pro
- acid sequence
- Prior art date
Links
- 102000004472 Myostatin Human genes 0.000 claims 7
- 108010056852 Myostatin Proteins 0.000 claims 7
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 238000005755 formation reaction Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000002797 proteolythic effect Effects 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Claims (15)
1. Izolirano protutijelo, naznačeno time, da posjeduje varijabilnu regiju teškog lanca koja sadrži aminokiselinski slijed od SEQ ID NO: 25 i varijabilnu regiju lakog lanca koja sadrži aminokiselinski slijed od SEQ ID NO: 31, pri čemu se protutijelo specifično veže na pro/latentni miostatin.
2. Izolirano protutijelo prema patentnom zahtjevu 1, naznačeno time, da protutijelo posjeduje teški lanac koji sadrži aminokiselinski slijed od SEQ ID NO: 50 i/ili laki lanac koji sadrži aminokiselinski slijed od SEQ ID NO: 51.
3. Izolirano protutijelo prema patentnom zahtjevu 1 ili zahtjevu 2, naznačeno time, da protutijelo jest ljudsko protutijelo.
4. Izolirano protutijelo prema bilo kojem od patentnih zahtjeva 1 do 3, naznačeno time, da protutijelo sadrži konstatnu domenu IgG4.
5. Izolirano protutijelo prema bilo kojem od patentnih zahtjeva 1 do 4, naznačeno time, da protutijelo sadrži konstatnu domenu IgG4 koja posjeduje supstituciju glavne okosnice od Ser do Pro, koja proizvodi zglob nalik na IgG1 i dopušta formiranje međulančanih disulfidnih veza.
6. Izolirano protutijelo prema bilo kojem od patentnih zahtjeva 1 do 5, naznačeno time, da protutijelo inhibira proteolitičke formacije zrelog miostatina putem toloidne proteaze.
7. Izolirano protutijelo prema patentnom zahtjevu 6, naznačeno time, da protutijelo inhibira proteolitičke formacije zrelog miostatina putem toloidne proteaze s IC50 koji je manji od 1 μM, i/ili križno reagira s ljudskim i mišjim pro/latentnim miostatinom.
8. Postupak in vitro za redukciju aktiviranja miostatinskog receptora u stanici koja se nalazi u mediju koji sadrži pro/latentni miostatin, naznačen time, da postupak obuhvaća dostavljanje u medij protutijela prema bilo kojem od patentnih zahtjeva 1 do 7, u količini koja je učinkovita za inhibiranje proteolitičkog aktiviranja pro/latentnog miostatina.
9. Protutijelo prema bilo kojem od patentnih zahtjeva 1 do 7, naznačeno time, da je za uporabu u postupku liječenja pojedinca koji ima miopatiju, pri čemu navedeni postupak obuhvaća davanje pojedincu učinkovite količine spomenutog protutijela.
10. Farmaceutski pripravak, naznačen time, da sadrži protutijelo prema bilo kojem od patentnih zahtjeva 1 do 7, i farmaceutski prihvatljiv nosač.
11. Farmaceutski pripravak prema patentnom zahtjevu 10, naznačen time, da pripravak je: (i) liofilizirani pripravak, (ii) tekući pripravak, ili (iii) smrznut.
12. Farmaceutski pripravak prema patentnom zahtjevu 11(iii), naznačen time, da je pripravak smrznut na temperaturi koja iznosi -65°C ili manje.
13. Štrcaljka, naznačena time, da sadrži farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 10 do 12.
14. Izolirana nukleinska kiselina, naznačena time, da kodira protutijelo koje posjeduje varijabilnu regiju teškog lanca sa slijedom nukleinske kiseline od SEQ ID NO: 39 i varijabilnu regiju lakog lanca sa slijedom nukleinske kiseline od SEQ ID NO: 45.
15. Izolirana stanica, naznačena time, da sadrži izoliranu nukleinsku kiselinu prema patentnom zahtjevu 14.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562219094P | 2015-09-15 | 2015-09-15 | |
EP16774748.4A EP3350220B1 (en) | 2015-09-15 | 2016-09-15 | Anti-pro/latent-myostatin antibodies and uses thereof |
PCT/US2016/052014 WO2017049011A1 (en) | 2015-09-15 | 2016-09-15 | Anti-pro/latent-myostatin antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211081T1 true HRP20211081T1 (hr) | 2021-10-15 |
Family
ID=57043000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211081TT HRP20211081T1 (hr) | 2015-09-15 | 2021-07-06 | Anti-pro/latentna miostatinska protutijela i njihove uporabe |
Country Status (24)
Country | Link |
---|---|
US (3) | US10751413B2 (hr) |
EP (2) | EP3350220B1 (hr) |
JP (3) | JP7107836B2 (hr) |
KR (2) | KR20230155021A (hr) |
CN (4) | CN108350067B (hr) |
AU (2) | AU2016323447B2 (hr) |
BR (1) | BR112018004981A2 (hr) |
CA (1) | CA3036652A1 (hr) |
CO (1) | CO2018002703A2 (hr) |
CY (1) | CY1124619T1 (hr) |
DK (1) | DK3350220T3 (hr) |
EA (1) | EA038146B1 (hr) |
ES (1) | ES2881642T3 (hr) |
HK (1) | HK1258267A1 (hr) |
HR (1) | HRP20211081T1 (hr) |
HU (1) | HUE055331T2 (hr) |
IL (2) | IL305148A (hr) |
LT (1) | LT3350220T (hr) |
MX (5) | MX2018003196A (hr) |
PL (1) | PL3350220T3 (hr) |
PT (1) | PT3350220T (hr) |
RS (1) | RS62330B1 (hr) |
SI (1) | SI3350220T1 (hr) |
WO (1) | WO2017049011A1 (hr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
EP2889376A4 (en) | 2012-08-24 | 2016-11-02 | Chugai Pharmaceutical Co Ltd | ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE |
TWI717591B (zh) | 2012-08-24 | 2021-02-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
WO2016073853A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
AR103161A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso |
KR20170110129A (ko) | 2015-02-05 | 2017-10-10 | 추가이 세이야쿠 가부시키가이샤 | 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용 |
MX2018003196A (es) | 2015-09-15 | 2019-05-16 | Scholar Rock Inc | Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos. |
EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
US10287345B2 (en) | 2016-01-08 | 2019-05-14 | Scholar Rock, Inc. | Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies |
HUE051480T2 (hu) | 2016-06-13 | 2021-03-01 | Scholar Rock Inc | Miosztatin-inhibitorok alkalmazása és kombinációs terápiák |
EP3494991A4 (en) | 2016-08-05 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8 |
JP7198757B2 (ja) | 2017-01-06 | 2023-01-04 | スカラー ロック インコーポレイテッド | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
WO2018129395A1 (en) * | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
WO2020014460A1 (en) | 2018-07-11 | 2020-01-16 | Scholar Rock, Inc. | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF |
HUE056501T2 (hu) | 2018-07-11 | 2022-02-28 | Scholar Rock Inc | Izoforma-szelektív TGF-béta1 inhibitorok és alkalmazásuk |
MX2021009175A (es) * | 2019-01-30 | 2021-09-14 | Scholar Rock Inc | Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos. |
MX2022001938A (es) * | 2019-08-28 | 2022-03-11 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-tgf-beta 1 latente y metodos de uso. |
JP2023511255A (ja) | 2020-01-11 | 2023-03-17 | スカラー ロック インコーポレイテッド | TGF-β阻害剤及びその使用 |
RU2750267C1 (ru) * | 2020-02-07 | 2021-06-25 | Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» | Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата |
MX2023004763A (es) | 2020-10-26 | 2023-05-09 | Scholar Rock Inc | Uso de anticuerpo anti-promiostatina/miostatina latente para tratar la atrofia muscular espinal. |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
AU2022299185A1 (en) | 2021-06-23 | 2024-01-25 | Scholar Rock, Inc. | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
WO2023215384A2 (en) | 2022-05-04 | 2023-11-09 | Scholar Rock, Inc. | Use of myostatin inhibitor for treating spinal muscular atrophy |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
WO1995013796A1 (en) | 1993-11-16 | 1995-05-26 | Depotech Corporation | Vesicles with controlled release of actives |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
JP2752788B2 (ja) | 1989-01-23 | 1998-05-18 | カイロン コーポレイション | 感染および過剰増殖障害の為の組換え療法 |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
EP1026253B2 (en) | 1989-03-21 | 2012-12-19 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
CA2066053C (en) | 1989-08-18 | 2001-12-11 | Harry E. Gruber | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
AU1545692A (en) | 1991-03-01 | 1992-10-06 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
JP3672306B2 (ja) | 1991-04-10 | 2005-07-20 | ザ スクリップス リサーチ インスティテュート | ファージミドを使用するヘテロ二量体受容体ライブラリー |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
ATE237694T1 (de) | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION. |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
EP0911413A3 (en) | 1992-12-03 | 2000-11-15 | Genzyme Corporation | Minimal adenovirus-based gene therapy vector |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
JPH09507829A (ja) | 1993-03-19 | 1997-08-12 | ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | 増殖分化因子−8 |
US7566768B1 (en) * | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
ES2188612T3 (es) | 1993-04-22 | 2003-07-01 | Skyepharma Inc | Liposomas multivesiculares de ciclodextrina para encapsular compuestos farmacologicos y metodos para su uso. |
AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
DE69433461T2 (de) | 1993-09-15 | 2004-11-18 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Rekombinanter Alphavirus Vektor |
CA2173975C (en) | 1993-10-25 | 2007-06-12 | Richard J. Gregory | Recombinant adenoviral vector and methods of use |
CA2158977A1 (en) | 1994-05-09 | 1995-11-10 | James G. Respess | Retroviral vectors having a reduced recombination rate |
CA2194660C (en) | 1994-07-08 | 2009-09-29 | Se-Jin Lee | Growth differentiation factor-11 |
US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
ATE424463T1 (de) | 1996-05-06 | 2009-03-15 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
EP1158997A2 (en) | 1999-03-09 | 2001-12-05 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
WO2001055086A1 (en) | 2000-01-28 | 2001-08-02 | Novo Nordisk A/S | Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
NZ522700A (en) | 2000-06-16 | 2006-02-24 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
AU2011244851A1 (en) | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US8455627B2 (en) | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
EP1300419B1 (en) | 2001-10-05 | 2007-06-13 | Affimed Therapeutics AG | Antibody of human origin for inhibiting thrombocyte aggregation |
US20040219142A1 (en) | 2002-07-19 | 2004-11-04 | Abbott Laboratories S.A. | Treatment of skin and nail disorders using TNFalpha inhibitors |
CA2498044A1 (en) | 2002-09-16 | 2004-03-25 | Wyeth | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
AR047392A1 (es) * | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
EP1578799B8 (en) | 2002-12-02 | 2011-03-23 | Amgen Fremont Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
JP2007535912A (ja) | 2003-12-31 | 2007-12-13 | シェーリング−プラウ・リミテッド | 中和エピトープベースの増殖増強性ワクチン |
AU2005219441A1 (en) | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | ALK7 and myostatin inhibitors and uses thereof |
EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
KR20070026650A (ko) | 2004-05-27 | 2007-03-08 | 악셀레론 파마 인코포레이티드 | 케르베루스/코코 유도체 및 그의 용도 |
AU2005271523B2 (en) | 2004-08-03 | 2011-09-15 | Dyax Corp. | hk1-binding proteins |
US7566772B2 (en) | 2005-01-26 | 2009-07-28 | Amgen Fremont Inc. | Antibodies against interleukin-1β |
US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
US7807159B2 (en) * | 2005-04-25 | 2010-10-05 | Amgen Fremont Inc. | Antibodies to myostatin |
PT1915397E (pt) | 2005-08-19 | 2015-04-30 | Univ Pennsylvania | Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8 |
KR101135220B1 (ko) | 2005-10-06 | 2012-04-24 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
WO2007061995A2 (en) | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
WO2008067480A2 (en) | 2006-11-29 | 2008-06-05 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
WO2008119426A1 (en) | 2007-03-30 | 2008-10-09 | Merck Patent Gmbh | Birefingent layer with negative optical dispersion |
EP2162152A2 (en) | 2007-06-01 | 2010-03-17 | Biogen Idec MA, Inc. | Cripto binding molecules |
TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
US8952130B2 (en) | 2009-02-24 | 2015-02-10 | The Salk Institute For Biological Studies | Designer ligands of TGF-β superfamily |
KR101836501B1 (ko) | 2009-04-27 | 2018-03-08 | 노파르티스 아게 | 근육 성장을 증가시키기 위한 조성물 및 방법 |
EP2440576A4 (en) | 2009-06-08 | 2013-11-20 | Acceleron Pharma Inc | PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES |
NZ602294A (en) | 2010-03-10 | 2015-04-24 | Genmab As | Monoclonal antibodies against c-met |
TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
AR081556A1 (es) * | 2010-06-03 | 2012-10-03 | Glaxo Group Ltd | Proteinas de union al antigeno humanizadas |
EP2606066A1 (en) * | 2010-08-16 | 2013-06-26 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
US8551892B2 (en) | 2011-07-27 | 2013-10-08 | Asm Japan K.K. | Method for reducing dielectric constant of film using direct plasma of hydrogen |
EP2776042B1 (en) | 2011-11-11 | 2019-03-20 | Duke University | Combination drug therapy for the treatment of solid tumors |
US20130178454A1 (en) | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
KR101704893B1 (ko) | 2012-06-15 | 2017-02-08 | 화이자 인코포레이티드 | Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도 |
CA2890733A1 (en) | 2012-11-06 | 2014-05-15 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
EP2981822B1 (en) * | 2013-05-06 | 2020-09-02 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
EP2853898B1 (en) | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
CA2929574A1 (en) | 2013-11-11 | 2015-05-14 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety |
WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
WO2016073853A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
WO2016073906A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related immunoassays |
AR103161A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso |
AU2016249015B2 (en) | 2015-04-15 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with GDF8 inhibitors |
MX2018003196A (es) * | 2015-09-15 | 2019-05-16 | Scholar Rock Inc | Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos. |
US10287345B2 (en) | 2016-01-08 | 2019-05-14 | Scholar Rock, Inc. | Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies |
HUE051480T2 (hu) | 2016-06-13 | 2021-03-01 | Scholar Rock Inc | Miosztatin-inhibitorok alkalmazása és kombinációs terápiák |
JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
JP7198757B2 (ja) | 2017-01-06 | 2023-01-04 | スカラー ロック インコーポレイテッド | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
-
2016
- 2016-09-15 MX MX2018003196A patent/MX2018003196A/es unknown
- 2016-09-15 LT LTEP16774748.4T patent/LT3350220T/lt unknown
- 2016-09-15 PL PL16774748T patent/PL3350220T3/pl unknown
- 2016-09-15 HU HUE16774748A patent/HUE055331T2/hu unknown
- 2016-09-15 AU AU2016323447A patent/AU2016323447B2/en active Active
- 2016-09-15 CN CN201680065184.7A patent/CN108350067B/zh active Active
- 2016-09-15 EP EP16774748.4A patent/EP3350220B1/en active Active
- 2016-09-15 DK DK16774748.4T patent/DK3350220T3/da active
- 2016-09-15 RS RS20210987A patent/RS62330B1/sr unknown
- 2016-09-15 EA EA201890712A patent/EA038146B1/ru unknown
- 2016-09-15 EP EP21170667.6A patent/EP3922645A1/en active Pending
- 2016-09-15 CA CA3036652A patent/CA3036652A1/en active Pending
- 2016-09-15 KR KR1020237037152A patent/KR20230155021A/ko active Application Filing
- 2016-09-15 IL IL305148A patent/IL305148A/en unknown
- 2016-09-15 CN CN202111206951.0A patent/CN113912718A/zh active Pending
- 2016-09-15 PT PT167747484T patent/PT3350220T/pt unknown
- 2016-09-15 JP JP2018513591A patent/JP7107836B2/ja active Active
- 2016-09-15 BR BR112018004981-6A patent/BR112018004981A2/pt active Search and Examination
- 2016-09-15 ES ES16774748T patent/ES2881642T3/es active Active
- 2016-09-15 US US15/760,393 patent/US10751413B2/en active Active
- 2016-09-15 KR KR1020187010090A patent/KR102596852B1/ko active IP Right Grant
- 2016-09-15 CN CN202111206744.5A patent/CN113896789A/zh active Pending
- 2016-09-15 CN CN202111206864.5A patent/CN113896790A/zh active Pending
- 2016-09-15 IL IL258121A patent/IL258121B2/en unknown
- 2016-09-15 WO PCT/US2016/052014 patent/WO2017049011A1/en active Application Filing
- 2016-09-15 SI SI201631287T patent/SI3350220T1/sl unknown
-
2018
- 2018-03-14 MX MX2022005202A patent/MX2022005202A/es unknown
- 2018-03-14 CO CONC2018/0002703A patent/CO2018002703A2/es unknown
- 2018-03-14 MX MX2022005173A patent/MX2022005173A/es unknown
- 2018-03-14 MX MX2022005177A patent/MX2022005177A/es unknown
- 2018-03-14 MX MX2022005211A patent/MX2022005211A/es unknown
-
2019
- 2019-01-15 HK HK19100631.4A patent/HK1258267A1/zh unknown
-
2020
- 2020-06-24 US US16/946,483 patent/US11439704B2/en active Active
-
2021
- 2021-07-06 HR HRP20211081TT patent/HRP20211081T1/hr unknown
- 2021-08-10 CY CY20211100716T patent/CY1124619T1/el unknown
-
2022
- 2022-07-12 JP JP2022111605A patent/JP7418508B2/ja active Active
- 2022-07-21 US US17/814,221 patent/US20230190929A1/en active Pending
-
2023
- 2023-06-21 AU AU2023203922A patent/AU2023203922A1/en active Pending
-
2024
- 2024-01-05 JP JP2024000878A patent/JP2024038278A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211081T1 (hr) | Anti-pro/latentna miostatinska protutijela i njihove uporabe | |
HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
HRP20201756T1 (hr) | Antitijela koja sadrže modificirane regije teškog lanca | |
HRP20191704T1 (hr) | Multispecifična protutijela | |
EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
PE20240096A1 (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador | |
HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
RS53042B (en) | ANTIBODIES AGAINST ERBB3 AND THEIR USES | |
HRP20151215T1 (hr) | Anti-nr10 protutijela i njihova uporaba | |
JP2017163973A5 (hr) | ||
HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
JP2014221758A5 (hr) | ||
PE20211272A1 (es) | POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO | |
BR112019003775A2 (pt) | anticorpo monoclonal anti-pd1, composição farmacêutica do mesmo e uso dos mesmos | |
AR108663A1 (es) | ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
FI3677591T3 (fi) | Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b | |
PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
PE20140218A1 (es) | Composicion farmaceutica | |
PE20141188A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
GEP20115324B (en) | Tweak binding antibodies | |
RS54423B1 (en) | ANTI-IGF ANTIBODIES | |
PE20170912A1 (es) | Conjugados de anticuerpo-farmaco |